Conditions: Ulcerative Colitis (UC)
Interventions: Drug: 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab; Drug: 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib; Drug: 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab; Drug: 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab)
Sponsors: University Hospital, Clermont-Ferrand; Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives
Not yet recruiting Conditions: Ulcerative Colitis (UC)
Interventions: Drug: 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab; Drug: 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib; Drug: 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab; Drug: 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab)
Sponsors: University Hospital, Clermont-Ferrand; Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives
Not yet recruiting
